Potential clinical impact of T-cell lymphocyte kinetics monitoring in patients with B cell precursors acute lymphoblastic leukemia treated with blinatumomab: a single-center experience

Blinatumomab is a bispecific anti-CD3 and anti-CD19 antibody that acts as a T-cell engager: by binding CD19+ lymphoblasts, blinatumomab recruits cytotoxic CD3+ T-lymphocytes to target the cancer cells. Here we describe seven different patients affected by B-cell precursor acute lymphoblastic leukemi...

Descripción completa

Detalles Bibliográficos
Autores principales: Duminuco, Andrea, Markovic, Uros, Parrinello, Nunziatina Laura, Lo Nigro, Luca, Mauro, Elisa, Vetro, Calogero, Parisi, Marina, Maugeri, Cinzia, Fiumara, Paolo Fabio, Milone, Giuseppe, Romano, Alessandra, Di Raimondo, Francesco, Leotta, Salvatore
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10556455/
https://www.ncbi.nlm.nih.gov/pubmed/37809082
http://dx.doi.org/10.3389/fimmu.2023.1195734

Ejemplares similares

Ejemplares similares